A citrullinated antigenic vaccine in treatment of autoimmune arthritis
Jin Xu, Tianya Dong, Qian Wang, Yang Xie, Xiangyu Fang, Chaonan Wei, Shuyan Liu, Xi Zheng, Ping Wang, Danxue Zhu, Lulu Cao, Suwei Dong, Kechi Fang, Chao Zhong, Jing Wang, Fanlei Hu, Zhanguo Li
Abstract
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease triggered by antigenic peptides with environmental and genetic risk factors. It has been shown that antigen-specific targeting could be a promising therapeutical strategy for RA by restoring immune tolerance to self-antigens without compromising normal immunity. Citrullination of antigens enhances antigenic properties and induces autoimmune responses. Here, we showed that citrullinated antigenic (citAg) vaccine ameliorated collagen-induced arthritis with decreased T-helper 1 (Th1) and Th17 cells, downregulated proinflammatory cytokines including interlukin-6 and tumor necrosis factor-α, and inhibited antigen recall responses. B cell receptor sequencing further revealed that citAg vaccine could dampen the dysregulated V(D)J recombination, restoring the immune repertoire. Taken together, the results demonstrated that citAg vaccine might have a therapeutic effect on RA.